HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer

This publication has 70 references indexed in Scilit:

• Changes in an HER-2 Peptide Upregulating HLA-A2 Expression Affect Both Conformational Epitopes and CTL Recognition
  Journal of Immunotherapy, 1995
• Targeted Eradication of Ovarian Cancer Mediated by Intracellular Expression of Anti-erbB-2 Single-Chain Antibody
  Gynecologic Oncology, 1995
• Demonstration by Two-Color Flow Cytometry That Tyrosine Kinase Activity Is Required for Down-Modulation of the Oncogenic neu Receptor
  DNA and Cell Biology, 1994
• Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer
  Cancer, 1994
• Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene
  Cellular Immunology, 1993
• Resistance ofHER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events
  Cancer Immunology, Immunotherapy, 1993
• Clinical Significance of erbB-2 (HER-2/neu) Protein
  Cancer Investigation, 1992
• T‐cell recognition of oncogene products: A new strategy for immunotherapy
  Molecular Carcinogenesis, 1992
• Selection of monoclonal antibodies which induce internalization and phosphorylation of P185^HER2 and growth inhibition of cells with HER2/neu gene amplification
  International Journal of Cancer, 1991
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987